IDH1 and neoplasm: mIDH1 detection in plasma ctDNA and tumor tissue was concordant in 92% of samples (193/210)Among ivosidenib-treated patients, IDH1 mutation clearance occurred in 10/36 (28%) with PFS ≥ 2.7 months versus 0/40 with PFS < 2.7 monthsNo IDH1 mutation clearance was observed in any placebo-treated patients (n = 49), regardless of outcome